Prevision Medicine launches Breakthrough Drug Screening Test for AML

Prevision Medicine, a Swiss-based company and leader in functional precision oncology, today announced the clinical launch of its AML Drug Screening Test.

For research use only, the test is powered by the company’s proprietary PrevisionOne platform. The test is designed to help oncologists rapidly identify the most effective therapies for patients with acute myeloid leukemia (AML).

AML is one of the most aggressive and heterogeneous forms of blood cancer, and because of its rapid progression, treatment often needs to begin within just a few days. Prevision Medicine’s AML Drug Screening Test enables clinicians to make more informed, patient-specific treatment decisions by evaluating patient-derived malignant and non-malignant cells against more than 100 drugs and drug combinations, only requiring small samples of blood or bone marrow.

The AML Drug Screening Test is based on evidence collected through two previous interventional clinical trials (EXALT-1 and DARTT-1), showing significant clinical benefit for patients. The DARTT-1 interventional study demonstrated a positive Overall Survival (OS) ratio of 3.4 for patients receiving top recommended therapies based on the screening. This means that, on average, these patients lived more than three times as long as those receiving less recommended therapies.

Prevision Medicine’s AML Drug Screening Test is built on collaborations with several hospitals across Switzerland, Germany, and Austria, and draws on knowledge from 300+ AML patient samples. In the DARTT-1 clinical trial, the test achieved a 100% success rate in generating actionable clinical insights; i.e. every patient sample tested, yielded results that could directly guide treatment decisions.

AML presents a critical need for precision-guided treatment strategies, given its complexity and the urgency of care. PrevisionOne’s high-throughput drug screening platform provides oncologists with the clinical clarity they need to identify effective therapies quickly — evidence-backed insights that have already translated into improved patient survival in clinical studies.

Philip Zimmermann, CEO Prevision Medicine

Key Features of the AML Drug Screening Test

• An extensive drug panel evaluating up to 100 drugs and drug combinations per test, including all widely approved drugs for AML and for other hematological malignancies
• Tailored for rapid clinical adoption, with an average 72 hours turn-around time from sample reception to test report, empowering physicians with fast treatment decision options for their patients
• Generated by our Proprietary PrevisionOne platform, delivering functional, patient-specific drug response data on how their cells respond to different cancer drugs
• Rooted in Pharmacoscopy: The clinically most validated functional precision medicine method which uses image-based single-cell data to evaluate ex vivo patient drug responses

PrevisionOne represents the culmination of a decade of technical and clinical innovation in functional precision medicine, now enabling the release of our AML test, addressing a high unmet need from clinicians. Looking-forward, we are particularly excited about the RAPID-1 study, a Swissmedic-approved randomized interventional clinical trial, which will not only strengthen the clinical evidence base but also pave the way for more personalized treatment options for patients.

Berend Snijder, Doctor at the Botnar Institute of Immune Engineering